Zydus Cadila has received the final approval from the USFDA to market Desoximetasone Cream USP (US RLD Topicort Cream), 0.25%.
It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.
Desoximetasone is a strong corticosteroid, used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies and rash). It reduces the swelling, itching and redness that can occur in these types of conditions.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)